Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.33 |
| ▸ | LPL | P06858 | 4/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22256579 | 0.88 | SLCO1B1 (0.40) | SLCO1B1DGAT1HIF1AABCB11PDE3B | |
| SCHEMBL24287812 | 0.86 | SLCO1B1 (0.34) | SLCO1B1ABCB11PDE3BPDE3AS1PR1 | |
| SCHEMBL22256622 | 0.85 | SLCO1B1 (0.43) | SLCO1B1ABCB11PDE3BPDE3AS1PR1 | |
| SCHEMBL22257039 | 0.83 | SLCO1B1 (0.42) | SLCO1B1ABCB11PDE3BPDE3AS1PR1 | |
| SCHEMBL22256661 | 0.83 | SLCO1B1 (0.44) | SLCO1B1DGAT1HIF1AABCB11LIPG | |
| SCHEMBL22257087 | 0.82 | SLCO1B1 (0.34) | SLCO1B1PDE3BPDE3A | |
| SCHEMBL21107482 | 0.81 | SLCO1B1 (0.44) | SLCO1B1 | |
| SCHEMBL22256894 | 0.81 | SLCO1B1 (0.40) | SLCO1B1HIF1AABCB11LIPGLPL | |
| SCHEMBL19715922 | 0.81 | SLCO1B1 (0.60) | SLCO1B1ABCB11LIPGLPLPDE3B | |
| SCHEMBL24042959 | 0.80 | DGAT1 (0.43) | DGAT1LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3912975-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020147739-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | 武汉朗来科技发展有限公司 | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | LPAR1, LPAR2, LPAR4 | SLCO1B1 3685/4885DGAT1 157/4885HIF1A 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.